New Angle On Cell Adhesion

Cell adhesion has become a popular target in the past few years. Now Christopher Mirabelli, a founder of Isis Pharmaceuticals Inc., is leaving to form a start up in the same area, but with a new twist - it will focus on a different class of molecules than the average cell adhesion company.

Boston-based Leukon, which will be getting a new name this month, will focus on chemokines and chemokine receptors. According to Mirabelli, most other cell adhesion companies are looking at targets in the selectin and integrin pathways...